Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Preferred Stock Liabilities (2019)

Enliven Therapeutics has reported Preferred Stock Liabilities over the past 1 years, most recently at $77.8 million for Q4 2019.

  • Quarterly results put Preferred Stock Liabilities at $77.8 million for Q4 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was $77.8 million (changed N/A YoY), and the annual figure for FY2019 was $77.8 million, changed.
  • Preferred Stock Liabilities reached $77.8 million in Q4 2019 per ELVN's latest filing, up from $45.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $77.8 million in Q4 2019 and bottomed at $30.7 million in Q2 2019.